americanpharmaceuticalreviewMay 15, 2017
Milestone Pharmaceuticals announced positive data from its Phase 2 NODE-1 trial evaluating etripamil, for the acute treatment of patients with paroxysmal supraventricular tachycardia (PSVT), a potentially debilitating cardiac arrhythmia. The results from the Phase 2 NODE-1 trial show that etripamil demonstrated statistically significant efficacy compared to placebo for the acute termination of PSVT induced in an electrophysiology laboratory.
The NODE-1 trial was a multi-center, placebo-controlled, double-blinded dose ranging Phase 2 trial of intranasal administration of etripamil for the conversion of induced PSVT. The primary objective of the trial was to demonstrate superiority of at least one of four intranasal etripamil doses over placebo in terminating PSVT within 15 minutes when induced in an electrophysiology laboratory.
One-hundred and four (104) patients expecting an ablation procedure were randomized into one of four etripamil treatment groups (35, 70, 105, 140mg) or placebo. After 15 minutes, PSVT conversion rates were significantly higher in the patients receiving etripamil 70mg (87%; 20/23), 105mg (75%; 15/20) and 140mg (95%; 20/21) compared to 35 percent (13/20) receiving placebo (p-values less than 0.001, 0.05, 0.001, respectively, compared to placebo). The conversion rate for patients receiving etripamil 35mg was 65% (13/20) (not significant). The median time to PSVT conversion ranged from 1.82 to 3.03 minutes across all four etripamil treatment arms.
"PSVT is an unpredictable, debilitating disorder resulting in a significant number of emergency room visits each year," Bruce Stambler, MD, FHRS, Piedmont Heart Institute said. "A fast-acting therapy that can rapidly resolve the symptoms of PSVT would be paradigm changing, both for patients and the healthcare system. These data demonstrate the potential for etripamil to achieve this goal, and I look forward to seeing the NODE-1 results translate to a Phase 3 study in the at-home setting."
Secondary objectives of the trial were to establish a dose-related trend and evaluate the safety of etripamil. A plateauing of an efficacy response was seen starting at the 70mg dose, providing guidance for selection of the Phase 3 dose. Etripamil had an acceptable safety profile and was well tolerated. The most common adverse event was nasal discomfort and congestion. Some patients experienced a transient drop in blood pressure at the two highest doses of etripamil (105 and 140mg).
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: